Home
Research
Submit Article
News
Sectors
Advertise
Premium
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.
You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.
Two Week FREE Trial
About Us
About Us
Editorial Staff
Terms and Conditions
Privacy Policy
Contact Us
iStock Rating
A
Details...
Enter Symbol
Human Genome Sciences, Inc. (NASDAQ: HGSI)
Sector: Medical
Current Price :
$14.24
52 Week Low
$6.64
52 Week High
$21.01
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Human Genome Sciences, Inc.
Law Offices of Howard G. Smith Announces Investigation of Human Genome Sciences Inc. Board of Directors for Potential Breaches of Fiduciary Duty
Law Office of Brodsky & Smith, LLC Announces Investigation of Human Genome Sciences, Inc.
Human Genome Sciences Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Goldberg LLP
Ryan & Maniskas, LLP Announces Investigation of Human Genome Sciences Inc.
Robbins Umeda LLP Announces an Investigation of Human Genome Sciences, Inc.
Traders: Most Active Stocks: (OTCBB: CTDT), (NASDAQ: HGSI), (NASDAQ: AAPL), (NASDAQ: MAT)
The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Human Genome Sciences, Inc. in Connection with the Sale of the Company to GlaxoSmithKline plc
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes
Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDA
Booming Biotech Industry a Hotbed of Merger & Acquisition Activity and Speculation in 2012
Human Genome Sciences Responds To GSK Extension of Unsolicited Tender Offer
Research and Development Spending Increasing in Biotech Industry
Where Opportunity Is Found - Research & Analysis on Human Genome Sciences and Schlumberger Limited.
REPEAT/Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition Proposals
Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition Proposals
FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes
Human Genome Sciences Responds to GSK Extension of Unsolicited Tender Offer
Human Genome Sciences Announces Multiple Abstracts Related to BENLYSTA? and Systemic Lupus Erythematosus to Be Presented at the 2012 EULAR Annual European Congress of Rheumatology
Human Genome Sciences Response to GSK Press Release
A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human Genome Sciences
Human Genome Sciences Announces Adoption of Short-Term Stockholder Rights Plan
Human Genome Sciences Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders
Human Genome Sciences Board of Directors to Review Unsolicited Tender Offer From GlaxoSmithKline
Obesity Related Health Care Costs Total $190 Billion a Year -- Orexigen and Human Genome Look to Take Advantage
Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2012 Financial Results
Human Genome Sciences Announces Unsolicited Offer from GlaxoSmithKline; HGS Board of Directors Authorizes Exploration of Strategic Alternatives
FYI from Human Genome Sciences: GlaxoSmithKline Announces Further Data from Phase 3 Trials of Albiglutide
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Barclays Capital Conference
Human Genome Sciences Announces Fourth-Quarter and Full-Year Financial Results and Key Developments
Arena Pharmaceuticals and Human Genome Sciences Continue 2012 Upswing
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference
Perception, Opportunity in Volatility - Research & Analysis on Human Genome Sciences and Merck & Co., Inc.
Zeldes & Haeggquist, LLP Announces Investigation of Human Genome Sciences, Inc. (HGSI)
Human Genome Sciences and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA?) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
Maven Semantic: Novel Antigen Research Database
The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in Human Genome Sciences, Inc. of Class Action Lawsuit and the Deadline of January 10, 2012 to Seek a Lead Plaintiff Position
Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against Human Genome Sciences, Inc.
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Human Genome Sciences, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the January 10, 2012 Lead Plaintiff Deadline
Izard Nobel LLP Announces Class Action Lawsuit Against Human Genome Sciences, Inc.
Market Considerations in Europe Outlook - Featured Research on Human Genome Sciences and Ford Motor Company
Maven Semantic: Therapeutic Proteins Research Database
Europe Situation Forecasts Change - Report Highlights Ford Motor Company and Human Genome Sciences
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference
Human Genome Sciences Completes Offering of $494.5?Million of Convertible Senior Notes
Human Genome Sciences Announces Multiple Abstracts Related to BENLYSTA? and Systemic Lupus Erythematosus to Be Presented at the 2011 ACR/ARHP Annual Scientific Meeting
Human Genome Sciences Announces Exercise of Option to Purchase Additional Notes for Total Convertible Notes Issuance of $494.5 Million
Human Genome Sciences Prices $430 Million Convertible Notes Issuance
Human Genome Sciences Announces Third Quarter 2011 Financial Results and Key Developments
What's Ahead: Today's Economic Outlook - Equity Research on Human Genome Sciences and Pharmaceutical Product Development, Inc.
Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2011 Financial Results
Equity Research on Gilead Sciences Inc. and Human Genome Sciences Inc. - Regulatory Approval Key for Biotech Companies
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bank of America Merrill Lynch Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Morgan Stanley Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Baird Conference
Human Genome Sciences Names Craig C. Parker Senior Vice President, Strategy and Corporate Development
Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2011 Financial Results
Maven Semantic: Cancer Drug Toxicology Research Database
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference
Analyst Research on Gilead Sciences Inc. and Human Genome Sciences Inc. -- Biotechnology Sector Benefits When Regulators Say 'OK'
Human Genome Sciences to Host May 20 Conference Call to Discuss the Positive Opinion Received in Europe from the CHMP for BENLYSTA(R) (Belimumab)
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA(R) (Belimumab)
Human Genome Sciences Appoints Allan Baxter, Ph.D., to Its Board of Directors
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
Human Genome Sciences Announces First Quarter 2011 Financial Results and Key Developments
Human Genome Sciences Updates Investors on Progress of BENLYSTA(R) Launch and Future Priorities
Biotech Posts Strong First Quarter Gain, The Burrill Report Finds
Maven Semantic: Cancer Vaccine Research Database
Human Genome Sciences and FivePrime Therapeutics Announce Development and Commercialization Agreement for Novel Anti-Cancer Drug
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Barclays Capital Conference
Human Genome Sciences Appoints George Morrow to its Board of Directors
First new lupus drug in 50 years
Maven Semantic: Novel Protein Target Database
Human Genome Sciences and GlaxoSmithKline Announce FDA Approval of BENLYSTA(R) (Belimumab) for Treatment of Systemic Lupus Erythematosus
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen and Company Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at RBC Capital Conference
Human Genome Sciences Announces Fourth-Quarter and Full-Year Financial Results and Key Developments
Maven Semantic: Protein Expression Research Database
Maven Semantic: Cell Signaling Database
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Leerink Swann Conference
Maven Semantic: Molecular Recognition Research Database
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at ISI Annual Conference
Human Genome Sciences and GlaxoSmithKline Announce Publication of BLISS-52 Phase 3 Study Results for BENLYSTA(R) in The Lancet
Maven Semantic: B-Cell Biology Research Database
Maven Semantic: In Situ Hybridization Database
Maven Semantic: Applied Genomics Research Database
Human Genome Sciences Appoints Greg Norden to Its Board of Directors
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Human Genome Sciences, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit
Maven Semantic: High-Throughput Screening Research Database
Human Genome Sciences Reports Progress Toward Sustainable Revenues and Announces 2011 Goals at JPMorgan Healthcare Conference
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference
Maven Semantic: Lymphocyte Activation Research Database
Maven Semantic: Immunization Research Database
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##